Mohamed Bouattour, Eric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre – 1 September 2017 – Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy.

Frailty is a critical determinant of outcomes in patients with cirrhosis. In this webinar we will present practical methods to assess and quantify frailty in both the outpatient and inpatient clinical settings. We will also provide recommendations on specific interventions once frailty is identified.Jody Olson (Moderator) Dr.

Laura Kulik, Julie K. Heimbach, Feras Zaiem, Jehad Almasri, Larry J Prokop, Zhen Wang, M. Hassan Murad, Khaled Mohammed – 31 August 2017 – Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist.

Bing‐liang Lin – 31 August 2017

Sheetal Trivedi, Satyapramod Murthy, Himanshu Sharma, Alex S. Hartlage, Arvind Kumar, Sashi V. Gadi, Peter Simmonds, Lokendra V. Chauhan, Troels K.H. Scheel, Eva Billerbeck, Peter D. Burbelo, Charles M. Rice, W. Ian Lipkin, Kurt Vandegrift, John M. Cullen, Amit Kapoor – 31 August 2017 – The lack of a relevant, tractable, and immunocompetent animal model for hepatitis C virus (HCV) has severely impeded investigations of viral persistence, immunity, and pathogenesis.

George V. Papatheodoridis, Spilios Manolakopoulos, Tung‐Hung Su, Spyros Siakavellas, Chun‐Jen Liu, Anastasia Kourikou, Hung‐Chih Yang, Jia‐Horng Kao – 31 August 2017 – Relapses are observed in most hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B patients who discontinue treatment with nucleos(t)ide analogues (NAs); however, the rates of relapse vary widely among studies, and whether all patients with relapse need retreatment is unclear.

Lewis R. Roberts, Claude B. Sirlin, Feras Zaiem, Jehad Almasri, Larry J. Prokop, Julie K. Heimbach, M. Hassan Murad, Khaled Mohammed – 31 August 2017 – Multiphasic computed tomography (CT) and magnetic resonance imaging (MRI) are both used for noninvasive diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. To determine if there is a relative diagnostic benefit of one over the other, we synthesized evidence regarding the relative performance of CT, extracellular contrast–enhanced MRI, and gadoxetate‐enhanced MRI for diagnosis of HCC in patients with cirrhosis.

Jan Pfeiffenberger, Sandra Beinhardt, Daniel N. Gotthardt, Nicola Haag, Clarissa Freissmuth, Ulrike Reuner, Annika Gauss, Wolfgang Stremmel, Michael L. Schilsky, Peter Ferenci, Karl Heinz Weiss – 31 August 2017 – Wilson's disease (WD) is a rare inherited disorder of copper metabolism causing toxic hepatic and neural copper accumulation. Clinical symptoms vary widely, from asymptomatic disease to acute liver failure or chronic liver disease with or without neuropsychiatric symptoms.

Yu‐Fu Zhou, Xiao‐Mei Wu, Gan Zhou, Ming‐dao Mu, Fa‐Li Zhang, Fe‐Mi Li, Christopher Qian, Fang Du, Wing‐Ho Yung, Zhong‐Ming Qian, Ya Ke – 31 August 2017 – Cystathionine β‐synthase (CBS) catalyzes the transsulfuration pathway and contributes, among other functions, to the generation of hydrogen sulfide. In view of the exceptionally high expression of CBS in the liver and the common interleukin‐6 pathway used in the regulatory systems of hydrogen sulfide and hepcidin, we speculate that CBS is involved in body iron homeostasis.

Elena Piccinin, Claudia Peres, Elena Bellafante, Simon Ducheix, Claudio Pinto, Gaetano Villani, Antonio Moschetta – 31 August 2017 – The peroxisome proliferator‐activated receptor γ (PPARγ) coactivator‐1β (PGC‐1 β) is a master regulator of mitochondrial biogenesis and oxidative metabolism as well as of antioxidant defense. Specifically, in the liver, PGC‐1β also promotes de novo lipogenesis, thus sustaining cellular anabolic processes.